PATENT CLAIM ANALYSIS

Application Number: 16073597
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["546", "081000"]

Abstract:
The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q 1 , Q 2 , Q 3 , Q 4 , R 1 , R 2 , R 4  and R 5  are as defined in claim  1.  The invention also relates to pharmaceutical compositions or medicaments comprising the compounds of the invention and processes for manufacturing these compounds and their intermediates.

Claim (Index 10):
The method of  claim 8 , wherein the myosin 2 mediated disease is selected from schizophrenia, cerebral ischemia, stroke, neuropathic pain, spinal cord injury, Alzheimer's disease, Parkinson's disease, addiction, brain cancer and multiple sclerosis.

Metadata:
- Claim Count in Document: 46.0
- Percentile: 95.0
- Lexical Diversity: 1.65455
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15941313', '15207718', '10739208', '10541328', '15254517']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.748431556217141
- 35 USC 102 Novelty (BERT): 0.5312508103993636
- Combined Prediction Score: 0.7267134816353633
- Mean Citation Score: 235.52492400000003
- Max Citation Score: 256.17014
- Similarity Product: 116.74043809096815

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test